🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesGLP-1 and atrial fibrillation risk — emerging signal or noise?

GLP-1 and atrial fibrillation risk — emerging signal or noise?

Dr.RaviCardio Sun, May 31, 2026 at 5:32 PM 15 replies 423 viewsPage 1 of 3
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
May 31, 2026 at 5:32 PM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity, without diabetes. The effect appeared earlier than the weight-loss curve can comfortably explain, which is the basis for arguing that some of the benefit is direct — anti-inflammatory and vascular — rather than purely a consequence of weight.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

What I actually want to know is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical. I would rather have one careful answer than five confident ones.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
37 7pete_manc_UK, anna.melb_AU, mark_tokyo and 34 others
Reply Quote Save Share Report
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
May 31, 2026 at 5:51 PM#2
Dr.RaviCardio said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

References:
[1] Zheng SL, et al. Lancet Diabetes Endocrinol. 2023;11(12):869-879.
36 6mike_nyc, VendorMark, COA_Karl and 33 others
Reply Quote Save Share Report
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
May 31, 2026 at 6:10 PM#3
Dr.RaviCardio said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

I read this differently from Dr.RaviCardio, on substance rather than tone. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

35 5jennifer_SEA, tyler_CSCS, VanRx_Mike and 32 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
jim_asheville
Member
289
1,234
Aug 2024
Asheville, NC
May 31, 2026 at 6:29 PM#4
Dr.GutHealth said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

I'm 48 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

15 months later: down 52 lbs, off atorvastatin, A1C from 8.4% to 5.3%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

34 4wanda_boise, NurseAsh_DET, BenResearch_OR and 31 others
Reply Quote Save Share Report
PeptideSynthNJ
Member
234
1,234
Aug 2024
Princeton, NJ
May 31, 2026 at 8:09 PM#5
DataDave said:
Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated…

This matches mine closely enough to be worth saying so out loud. I had assumed I was the exception until I read this.

33 3Dr.RaviCardio, jennifer_SEA, tyler_CSCS and 30 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register